Ultragenyx shares more than double in IPO debut

Published on NewsOK Modified: January 31, 2014 at 11:32 am •  Published: January 31, 2014

NEW YORK (AP) — Shares of Ultragenyx have more than doubled in their trading debut after the drug developer's initial public offering raised $121 million.

The Novato, Calif., company is developing several possible treatments for rare or extremely rare diseases, including Sly Syndrome, a cellular and organ dysfunction that typically leads to death by early adulthood.

Ultragenyx Pharmaceutical Inc. sold 5.8 million shares at $21 each, well above its mid-January forecast of 4.8 million shares going for $14 to $17.

The stock climbed $24 to $45 per share in midday trading Friday.

Two other drug developers debuted on the public market Friday: Trevena Inc., which raised about $64.8 million, and Cara Therapeutics Inc. in a $55 million IPO.

Trevena stock is off 6.1 percent and Cara shares are up almost 21 percent.

Trending Now


  1. 1
    Report: Caron Butler close to two-year deal with Detroit Pistons
  2. 2
    It’s harder to be a poor student in the U.S. than in Russia
  3. 3
    Man fatally stabbed in west Tulsa early Sunday
  4. 4
    How brain imaging can be used to predict the stock market
  5. 5
    Bridenstine tours Fort Sill, satisfied with facility's transparency
+ show more